Inovio CEO to Speak on Viral Epidemic Preparedness Panel at BIO International Convention
May 31 2018 - 8:00AM
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr.
J. Joseph Kim, President and CEO, will address Inovio’s ability to
respond to emerging viral threats at the Biotechnology Industry
Organization’s annual international convention, June 4-7 in Boston,
MA. Dr. Kim will join other world leaders in pandemic response on a
panel:
From One Epidemic to the Next: Learning
from Ebola and ZikaJune 5, 2018 at 11 AM
ET
The panel will use the most recent experiences
with Ebola and Zika to discuss the challenges of vaccine
development in the midst of a global public health emergency with
experts from industry, government and partner organizations.
Experts from industry, government and partner organizations will
consider whether existing systems, mechanisms and incentives for
vaccine development are sufficient to prepare us for the next
epidemic threat. Joining Dr. Kim on the panel are these government,
non-government and commercial leaders: Richard Hatchett, CEO, CEPI;
Rick Bright, Director, BARDA; Julia Spencer, Executive Director,
Global Vaccines Public Policy, Merck & Co.; and Nima Farzan,
CEO, PaxVax.
Inovio was the first organization to develop,
manufacture and report positive human data from a Zika vaccine in
less than seven months – when traditional vaccines take several
years to reach this point. These results were published in the
October 2017 – New England Journal of Medicine. By utilizing both
the capabilities and versatility of Inovio’s DNA-based
immunotherapies and vaccines, Inovio is poised to combat
well-established pathogens with significant unmet needs to new and
emerging threats around the world, while also offering treatment
alternatives and prevention of multiple cancers and infectious
diseases.
In addition to the recent Zika publication,
Inovio recently announced a $56 million partnership with the
Coalition for Epidemic Preparedness Innovations (CEPI) under which
Inovio will develop vaccine candidates against two emerging viral
threats: Lassa fever and Middle East Respiratory Syndrome (MERS).
Inovio is also advancing its vaccines in clinical trials against
HIV, Ebola and hepatitis B infection, in both preventive and
therapeutic modalities.
About Inovio Pharmaceuticals,
Inc.
Inovio is a late-stage biotechnology company
focused on the discovery, development, and commercialization of DNA
immunotherapies that transform the treatment of cancer and
infectious diseases. Inovio’s proprietary platform technology,
ASPIRE, applies next-generation antigen sequencing and DNA delivery
to activate potent immune responses to targeted diseases. The
technology functions exclusively in vivo, and has been demonstrated
to consistently activate robust and fully functional T cell and
antibody responses against targeted cancers and pathogens. Inovio
is the only immunotherapy company that has reported generating T
cells whose killing capacity correlates with relevant clinical
outcomes. Inovio’s most advanced clinical program, VGX-3100, is in
Phase 3 for the treatment of HPV-related cervical precancer. Also
in development are Phase 2 immuno-oncology programs targeting head
and neck cancer, bladder cancer, and glioblastoma, as well as
platform development programs in hepatitis B, Zika, Ebola, MERS,
and HIV. Partners and collaborators include MedImmune, Regeneron,
Roche/Genentech, ApolloBio Corporation, The Wistar Institute,
University of Pennsylvania, the Parker Institute for Cancer
Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life
Sciences, Drexel University, NIH, HIV Vaccines Trial Network,
National Cancer Institute, U.S. Military HIV Research Program, and
Laval University. For more information, visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs, including the planned initiation
and conduct of clinical trials and the availability and timing of
data from those trials, and our plans and expectations regarding
partnerships. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials and product development programs, the availability of
funding to support continuing research and studies in an effort to
prove safety and efficacy of electroporation technology as a
delivery mechanism or develop viable DNA vaccines, our ability to
support our pipeline of SynCon® active immunotherapy and vaccine
products, the ability of our collaborators to attain development
and commercial milestones for products we license and product sales
that will enable us to receive future payments and royalties, the
adequacy of our capital resources, the availability or potential
availability of alternative therapies or treatments for the
conditions targeted by us or our collaborators, including
alternatives that may be more efficacious or cost effective than
any therapy or treatment that we and our collaborators hope to
develop, issues involving product liability, issues involving
patents and whether they or licenses to them will provide us with
meaningful protection from others using the covered technologies,
whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand
claims of invalidity and whether we can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
our technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government
healthcare proposals and other factors set forth in our Annual
Report on Form 10-K for the year ended December 31, 2017, our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2018
and other regulatory filings we make from time to time. There can
be no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
CONTACTS:Investors:Media: |
|
Ben
Matone, Inovio, 484-362-0076, ben.matone@inovio.comJeff Richardson,
Inovio, 267-440-4211, jrichardson@inovio.com |
|
|
|
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Apr 2023 to Apr 2024